Comparing Biventricular Pacing and Left Bundle Branch Pacing for Heart Failure
Official title: Randomized Study of Integrated Evaluation of Conventional Biventricular and Left Bundle Branch Pacing Therapy Effect on Left Ventricular Remodeling and Clinical Outcomes in Patients With Chronic Heart Failure With Reduced Ejection Fraction
Run by Tomsk National Research Medical Center of the Russian Academy of Sciences · NCT05769036 · Data updated 2026-11-12
This study is testing whether a new way of pacing the heart can help people with heart failure feel better and improve their heart function compared to the standard method.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | Tomsk National Research Medical Center of the Russian Academy of Sciences Academic / other |
| Locations | 1 site (Tomsk) |
| Status | Recruiting |
| Started | October 1, 2023 |
| Main results expected | June 1, 2028 |
| Study ends | September 1, 2028 |
| Registry record updated | September 10, 2025 |
| Trial ID | NCT05769036 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 to 80 with symptomatic heart failure and specific heart function criteria.
✕Probably not a fit
Patients with heart failure who do not meet the inclusion criteria, such as those with certain arrhythmias or higher left ventricular ejection fractions, may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial aims to compare the outcomes of conventional biventricular pacing with left bundle branch pacing in patients suffering from heart failure. It focuses on individuals with ischemic and non-ischemic cardiomyopathy who have reduced left ventricular function and left bundle branch block. The study will involve the implantation of cardioverter-defibrillators equipped with either pacing method to assess their effectiveness in improving heart function and patient quality of life. The trial will monitor various clinical parameters and patient responses over time to determine which pacing strategy yields better results.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment options for heart failure patients, enhancing their quality of life and reducing hospitalizations.
How similar studies have gone: Other studies have shown promising results with similar pacing approaches, suggesting potential for success in this trial.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion criteria: 1. The patient is willing and able to comply with the protocol and has provided written informed consent; 2. Male or female patients aged 18 to 80 years; 3. Patients with ischemic or non-ischemic cardiomyopathy; 4. Symptomatic HF for at least 3 months prior to enrollment in the study; 5. New York Heart Association (NYHA) functional class HF ≥ II; 6. Patients with HF in sinus rhythm (SR) with LVEF ≤ 35% (measured in the last 6 weeks prior to enrollment), QRS duration ≥150 ms with LBBB morphology; 7. Patients with HF in SR with LVEF ≤ 35% (measured in the last 6 weeks prior to enrollment), QRS duration 130-149 ms with LBBB morphology; 8. Patients with HF in SR with LVEF ≤ 35% (measured in the last 6 weeks prior to enrollment), QRS duration ≥150 ms with non-LBBB morphology; 9. Patients with symptomatic persistent or permanent atrial fibrillation, HF with LVEF \< 40% (measured in the last 6 weeks prior to enrollment) and an uncontrolled heart rate who are candidates for atrioventricular junction ablation (irrespective of QRS duration); 10. Patients with HF, LVEF \< 40% (measured in the last 6 weeks prior to enrollment) and indications for continuous ventricular pacing due to bradycardia; 11. Patients who have received a conventional pacemaker or an implanted cardioverter-defibrillator and who subsequently develop symptomatic HF with LVEF \< 40% (measured in the last 6 weeks prior to enrollment) despite optimal medical therapy, and who have a significant proportion of right ventricle pacing; 12. Optimal HF medical therapy. Exclusion criteria: 1. Coronary artery (CA) bypass grafting, balloon dilatation or CA stenting within 3 months prior to enrollment; 2. Acute myocardial infarction within 3 months prior to enrollment; 3. Acute coronary syndrome; 4. Patients with planned cardiovascular intervention (CA bypass grafting, balloon dilatation or CA stenting); 5. Patients listed for heart transplant; 6. Patients with implanted cardiac assist device; 7. Acute myocarditis; 8. Infiltrative myocardial disease; 9. Hypertrophic cardiomyopathy; 10. Severe primary stenosis or regurgitation of the mitral, tricuspid and aortic valves; 11. Woman currently pregnant or breastfeeding or not using reliable contraceptive measures during fertility age; 12. Mental or physical inability to participate in the study; 13. Patients unable or unwilling to cooperate within the study protocol; 14. Patients with rheumatic heart disease; 15. Mechanic tricuspid valve patients; 16. Patients with any serious medical condition that could interfere with this study; 17. Enrollment in another investigational drug or device study; 18. Patients not available for follow-up; 19. Patients with severe chronic kidney disease (estimated glomerular filtration rate ˂ 30 ml/min/1.73 m2); 20. Life expectancy ≤ 12 months; 21. Participation in another telemonitoring concept.
Where it's running
-
Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences
Tomsk, Russia Recruiting
Study contacts
- Principal investigator: Tariel A Atabekov, Ph.D. — Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences
- Study coordinator: Tariel A Atabekov, Ph.D.
- Email: kgma1011@mail.ru
- Phone: +79528002625
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Improving heart failure treatment for patients who don't respond to standard therapy
This study is testing a new heart treatment using a special device for people with heart failure who haven't felt better with standard therapies, to see if it can improve their heart function and overall health.
-
Left bundle branch area pacing with multimodal guidance vs. conventional pacing for heart failure with complete left bundle branch block
A multicenter trial tests whether using multimodal data to guide left bundle branch area pacing helps people with heart failure and complete left bundle branch block, compared with traditional biventricular pacing.
-
PET imaging with XTR003 and 18F-FDG to find recoverable heart muscle in ischemic cardiomyopathy
This trial tests whether adding XTR003 injection to 18F‑FDG PET scans helps identify living heart muscle in adults (18–85) with ischemic cardiomyopathy who are candidates for complete revascularization.
-
18F-mFBG imaging to map heart nerve signals in people with ischemic heart failure and ICDs
Researchers are testing whether 18F-mFBG PET imaging can see heart nerve activity in people with ischemic heart failure and an ICD.
-
Using Apple Watch data to predict heart failure outcomes
This study is testing if data from Apple Watches can help predict heart failure problems and the chances of needing to go back to the hospital for patients with heart failure.
-
Using radiotherapy to treat advanced heart failure
This study is testing if a single low dose of radiation therapy can help people with advanced heart failure feel better and improve their heart function.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.